VistaGen Faces Legal Action After Phase 3 Trial Failure and 80% Stock Plunge

VistaGen's Troubled Trail: Legal Scrutiny Follows Clinical Trial Setback

VistaGen Therapeutics, Inc. faces significant scrutiny following the disappointing results of its Phase 3 PALISADE-3 clinical trial for fasedienol, an investigational drug aimed at treating social anxiety disorder. On December 17, 2025, the company reveals that the trial fails to demonstrate a statistically significant improvement in its primary endpoint, where fasedienol performed similarly to the placebo. This announcement leads to a dramatic collapse in the company's stock price, plunging over 80% from $4.36 per share to $0.86 per share. The substantial loss is raising alarms among shareholders, prompting legal action and calls for accountability from company executives accused of providing misleading information regarding the trial's potential and outcomes.

In the aftermath of the clinical trial announcement, both Gross Law Firm and Levi & Korsinsky, LLP declare class action lawsuits on behalf of affected shareholders. The complaints allege that VistaGen's executives made overly optimistic assertions about the trial while withholding information about known challenges. Assertions from COO Joshua Prince relating to operational aspects of the trial, including enrollment efforts, are under scrutiny, with claims indicating that he may have glossed over fundamental issues affecting trial success. In a competitive landscape where investor trust is paramount, the apparent misalignment between executive statements and trial realities intensifies the demand for scrutiny around clinical efficacy communication within the biotechnology sector.

The combined legal efforts urge shareholders who experienced financial losses between April 1, 2024, and December 16, 2025, to register for potential lead plaintiff status by March 16, 2026. Both law firms, each with strong reputations in securities litigation, emphasize that participating in the lawsuit carries no financial obligation. Their engagement highlights a broader trend in the biotech industry, where investor confidence can shift rapidly based on trial outcomes. As VistaGen navigates this challenging period, the focus remains on restoring credibility and addressing shareholder concerns amid ongoing litigation.

Additionally, the situation presents a critical moment for VistaGen to reassess its communication strategy with stakeholders. Transparent dialogue surrounding clinical trial expectations can strengthen investor relationships and foster trust. As the legal proceedings unfold, VistaGen’s ability to address these challenges will play a significant role in its future trajectory within the therapeutic landscape and its commitment to developing effective treatments for mental health conditions. Shareholders are keenly observing as the firm strives to rectify its path forward.